Belvedere Trading’s MacroGenics MGNX Stock Holding History

Belvedere Trading’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,400	Closed	-$20.6K	–	830
2024 Q1	$20.6K	Buy	+1,400	New	+$21.2K	﹤0.01%	567

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belvedere Trading's MGNX Position: Q2 2024 in Review

Belvedere Trading sold out of MacroGenics (MGNX) in Q2 2024, closing a stake of 17,501 shares — an estimated $258K sold.

Belvedere Trading first reported a position in MGNX in Q1 2024 and held it in 1 quarter. The position peaked at $258K in Q1 2024. 146 funds tracked by Wall St. Rank hold MGNX as of Q2 2024.

Belvedere Trading reported no remaining MacroGenics position as of Q2 2024 after selling out during the quarter.
Belvedere Trading sold 17,501 MacroGenics shares in Q2 2024, an estimated $258K.
Belvedere Trading first reported a position in MacroGenics in Q1 2024 and held it in 1 quarter.
Belvedere Trading's MacroGenics position peaked at $258K in Q1 2024.
146 funds tracked by Wall St. Rank held MacroGenics as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.